[
  {
    "ts": null,
    "headline": "Global Medical Aesthetic Devices Market to Reach $37.9 Billion by 2029",
    "summary": "“Discover how advances in device technology and regional demand shifts are reshaping the future of medical aesthetics in BCC Research’s latest market analysis.”Boston, Aug. 06, 2025 (GLOBE NEWSWIRE) -- As global demand for aesthetic enhancement rises, medical aesthetic devices are transforming how patients approach cosmetic care. From laser-based treatments to minimally invasive procedures, leading companies such as AbbVie, Alma Lasers, and Johnson & Johnson to invest in next-generation technolo",
    "url": "https://finnhub.io/api/news?id=56967104105c5ef6f3aee82a6f98c7fa69f1198581f88ef77670f2001b6c7496",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754498040,
      "headline": "Global Medical Aesthetic Devices Market to Reach $37.9 Billion by 2029",
      "id": 136238970,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "“Discover how advances in device technology and regional demand shifts are reshaping the future of medical aesthetics in BCC Research’s latest market analysis.”Boston, Aug. 06, 2025 (GLOBE NEWSWIRE) -- As global demand for aesthetic enhancement rises, medical aesthetic devices are transforming how patients approach cosmetic care. From laser-based treatments to minimally invasive procedures, leading companies such as AbbVie, Alma Lasers, and Johnson & Johnson to invest in next-generation technolo",
      "url": "https://finnhub.io/api/news?id=56967104105c5ef6f3aee82a6f98c7fa69f1198581f88ef77670f2001b6c7496"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=7a4160301c2941c2e98899d39491e036267ebf5e623a151f1250828fa7cb1cd0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754497860,
      "headline": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
      "id": 136250370,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=7a4160301c2941c2e98899d39491e036267ebf5e623a151f1250828fa7cb1cd0"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi",
    "summary": "Strong efficacy and safety perceptions, as well as favorable administration fuel utilization of the IL-23 class in Crohn’s disease, according to Spherix Global Insights.EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors and JAK inhibitors, continue displace long-standing therapies like TNF inhibitors. With the recent FDA approvals of Tremfya (guselkuma",
    "url": "https://finnhub.io/api/news?id=a9a707bf26bdf0acd2c2b56907ba2d4e4e4855af906cfc93b8196b3f35e10e4f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754494140,
      "headline": "Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi",
      "id": 136238959,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Strong efficacy and safety perceptions, as well as favorable administration fuel utilization of the IL-23 class in Crohn’s disease, according to Spherix Global Insights.EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors and JAK inhibitors, continue displace long-standing therapies like TNF inhibitors. With the recent FDA approvals of Tremfya (guselkuma",
      "url": "https://finnhub.io/api/news?id=a9a707bf26bdf0acd2c2b56907ba2d4e4e4855af906cfc93b8196b3f35e10e4f"
    }
  },
  {
    "ts": null,
    "headline": "Get Ready, JUVÉDERM® Day is Calling!",
    "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announces the return of JUVÉDERM® Day, Wednesday, August 20. This year's holiday marks the third annual celebration of aesthetics excellence with exciting offers exclusively for Allē Members.",
    "url": "https://finnhub.io/api/news?id=a70820d6966702d96c11dbf307d6be3f52bd1e2f0bb00555b9f8db7b1bd4c616",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754481600,
      "headline": "Get Ready, JUVÉDERM® Day is Calling!",
      "id": 136237184,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announces the return of JUVÉDERM® Day, Wednesday, August 20. This year's holiday marks the third annual celebration of aesthetics excellence with exciting offers exclusively for Allē Members.",
      "url": "https://finnhub.io/api/news?id=a70820d6966702d96c11dbf307d6be3f52bd1e2f0bb00555b9f8db7b1bd4c616"
    }
  },
  {
    "ts": null,
    "headline": "Hungary's Richter says some US exports face tariff challenges, but flagship drug exempt",
    "summary": "BUDAPEST (Reuters) -Higher U.S. tariffs may make it challenging for Hungarian pharmaceutical company Richter to export some products to the United States, but they won't apply to its flagship antipsychotic drug Vraylar, CEO Gabor Orban said on Wednesday.  President Donald Trump said on Tuesday the United States would initially place a \"small tariff\" on pharmaceutical imports before hiking it to 150% within 18 months, and eventually to 250%, to help boost domestic production.  However, a framework agreement between the U.S. and the European Union sets out that if the United States raises tariffs following its import investigation, they will be capped at 15%.",
    "url": "https://finnhub.io/api/news?id=987e726f8f7de38f83ce6a0be74b849829c47b84192cd38aaf456dd717498d2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754475411,
      "headline": "Hungary's Richter says some US exports face tariff challenges, but flagship drug exempt",
      "id": 136232227,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "BUDAPEST (Reuters) -Higher U.S. tariffs may make it challenging for Hungarian pharmaceutical company Richter to export some products to the United States, but they won't apply to its flagship antipsychotic drug Vraylar, CEO Gabor Orban said on Wednesday.  President Donald Trump said on Tuesday the United States would initially place a \"small tariff\" on pharmaceutical imports before hiking it to 150% within 18 months, and eventually to 250%, to help boost domestic production.  However, a framework agreement between the U.S. and the European Union sets out that if the United States raises tariffs following its import investigation, they will be capped at 15%.",
      "url": "https://finnhub.io/api/news?id=987e726f8f7de38f83ce6a0be74b849829c47b84192cd38aaf456dd717498d2d"
    }
  }
]